Provided by Tiger Trade Technology Pte. Ltd.

Candel Therapeutics, Inc.

10.55
-0.7850-6.93%
Post-market: 10.40-0.1450-1.38%19:54 EDT
Volume:3.60M
Turnover:37.46M
Market Cap:806.89M
PE:-7.33
High:11.41
Open:11.32
Low:9.86
Close:11.33
52wk High:14.00
52wk Low:4.35
Shares:76.52M
Float Shares:60.06M
Volume Ratio:3.76
T/O Rate:5.99%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4390
EPS(LYR):-0.7210
ROE:-81.84%
ROA:-28.64%
PB:6.40
PE(LYR):-14.63

Loading ...

Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting

GlobeNewswire
·
May 16

Canaccord Genuity Reaffirms Their Buy Rating on Candel Therapeutics (CADL)

TIPRANKS
·
May 15

Analysts Have Conflicting Sentiments on These Healthcare Companies: Humana (HUM), Pyxis Oncology (PYXS) and Candel Therapeutics (CADL)

TIPRANKS
·
May 15

Candel Therapeutics publishes corporate presentation on viral immunotherapies for solid tumors

Reuters
·
May 15

Candel Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 14

Candel Therapeutics reports Q1 loss

Reuters
·
May 14

Candel Therapeutics Q1 EPS $(0.14) Beats $(0.34) Estimate

Benzinga Earnings
·
May 14

BRIEF-Candel Therapeutics Q1 Net Income USD -8.861 Million

Reuters
·
May 14

Candel Therapeutics Q1 Operating Expenses USD 16.284 Million

THOMSON REUTERS
·
May 14

Press Release: Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Dow Jones
·
May 14

Candel Therapeutics CEO presents at Stifel Virtual Targeted Oncology Forum

Reuters
·
May 13

Candel Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire
·
May 13

Candel Therapeutics Inc expected to post a loss of 32 cents a share - Earnings Preview

Reuters
·
May 08

Candel Therapeutics updates Phase 3 CAN-2409 data in localized prostate cancer trial

Reuters
·
May 04

Candel Therapeutics grants new-hire inducement options for 29,400 shares at $6.18 each

Reuters
·
May 02

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
May 02

Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer

GlobeNewswire
·
Apr 29

Candel Therapeutics Stock Soars After Cantor Fitzgerald's Overweight Rating

Benzinga_recent_news
·
Apr 21

Candel Therapeutics Initiated at Overweight by Cantor Fitzgerald

Dow Jones
·
Apr 20

Candel Therapeutics publishes corporate presentation on viral immunotherapies for solid tumors

Reuters
·
Apr 15